# The Royal Wolverhampton Hospitals NHS Trust: Observational study in Myeloma Multiple (400 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | The Royal Wolverhampton Hospitals NHS Trust |
| Sponsor type | Non-US government |
| Study | RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab |
| NCT ID | NCT07891871 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | Myeloma Multiple |
| Target enrollment | 400 |
| Posted | 2026-10-23 |
| Planned start | 2026-11-15 |
| Event | Newly registered study |
| Event date | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- 400 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07891871). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.